"Genentech has given me the opportunity to perform translation research and lead technological innovation driven by a pursuit of understanding mechanistic biology."
I joined Genentech in 2016 after completing a postdoc at Harvard Medical School to pursue proteomic technology development within a translational setting. My research career has focused on developing and applying cutting-edge proteomics approaches to improve the identification and quantification of proteins, peptides, and post-translational modifications. I have continued these actives within Discovery Proteomics at Genentech where collaborations with biological researchers define the current limitations of our proteomic technologies. Once defined, my lab develops and implements new approaches that enable biological research and therapeutic discovery.
Currently, the two main focuses of my lab are: 1) development of mass spectrometry based real-time data analysis approaches to improve the quantitative depth of single-cell proteomics, and 2) development and application of MHC-I and MHC-II peptide analysis to better understand processing and presentation of cancer specific antigens within a tumor setting.
Genentech’s Postdoctoral Fellow program provides an excellent opportunity to perform basic research activities that lay the foundation for future translational studies. Postdoctoral projects are highly collaborative and offer the opportunity to work together with thought leaders across multiple disciplines. In my group, postdocs will explore mechanistic biology by employing innovative proteomics analyses.
Nat Methods 1–8 (2020) doi:10.1038/s41592-020-01002-5.
My lab is interested in developing and applying quantitative proteomics methods to explore biological pathways related to potential therapeutic targets. Technology development in the lab focuses on the use of real-time data analysis to improve the quantification of low-level proteomes. Specifically, we are developing methods to improve the depth of single cell proteomics analysis to enable quantification of therapeutically relevant target proteins. My lab also focuses on understanding protein processing and MHC presentation of peptides to the immune system. Working closely with collaborators in Cancer Immunology, we are developing methods to analyze MHC-I and MHC-II associated peptidomes to better understand antigen presentation by tumor cells.